Core Viewpoint - The company has extended the financial support agreement with its indirect controlling shareholder, Zhengzhou High-tech Investment Holding Group Co., Ltd., allowing for a borrowing limit of up to 1.2 billion yuan with a maximum interest rate of 4.2% per annum, aimed at supporting the company's operational funding needs [1][2][4]. Group 1: Related Transactions Basic Situation - The company approved a borrowing agreement with High-tech Investment Holding Group, allowing for loans up to 1.2 billion yuan, with an annual interest rate not exceeding 4.2% [1]. - The company has received loans of 419 million yuan and 157 million yuan from High-tech Investment Holding Group at interest rates of 4.0266% and 3.2966% per annum, respectively [1]. Group 2: Related Transactions Progress - The borrowing agreement's validity has been extended by one year, with the interest rate remaining aligned with the financing costs of similar loans from financial institutions [2][3]. - The company confirmed the borrowing terms with High-tech Investment Holding Group, which will continue to support the company financially, with the original borrowing rate applied until the contract's expiration [3]. Group 3: Financial Support Utilization - The financial support from the controlling shareholder is primarily used to supplement the company's operational funds, with no collateral required, enhancing the flexibility of debt financing [4]. - As of the announcement date, the outstanding balance of financial support received from High-tech Investment Holding Group is 284.7252 million yuan [4].
河南太龙药业股份有限公司 关于接受间接控股股东财务支持暨关联交易的进展公告